In a placebo-controlled trial of older adults with reduced muscle strength, 12 weeks of heat-treated Lactiplantibacillus plantarum MYO (LPMYO) significantly improved quadriceps strength, hand grip strength, and muscle quality index versus placebo. Stool sequencing showed increases in Faecalibacterium, Lachnospira, Turicibacter, Megasphaera, and the [Eubacterium] ventriosum group. Turicibacter and Megasphaera correlated positively with muscle measures, and predicted functions such as amino acid metabolism, nicotinamide metabolism, and oxidative phosphorylation were enriched.
The strength gains are the headline, and grip and leg strength are validated predictors of falls, disability, and mortality, so functional endpoints are the right ones to test. Still, caution is warranted. The abstract gives no sample size or effect magnitudes, so we cannot judge whether the improvements clear clinically meaningful thresholds. Twelve weeks is short, nothing is reported on falls or fractures, and the study appears to be a single-product trial from a company-affiliated lab, a profile that often shrinks on independent replication. The microbiome link is correlational: the functional predictions come from inferred gene content, not measured metabolites, so they cannot show that bacterial shifts caused the strength gains. The nicotinamide and OXPHOS signals are biologically plausible given how mitochondrial decline drives muscle aging, but they remain hypotheses. Heat-killed bacteria are attractive because they are shelf-stable and safe in frail people. Editorially, this is an encouraging but preliminary result. Resistance training and adequate protein remain the proven sarcopenia interventions, and any paraprobiotic should be viewed as an experimental adjunct until larger, independent trials confirm it.